Second, Kayadibi et al. posit that non-invasive tests could replace liver biopsy, but the clinical outcomes and cost-effectiveness of this strategy in this population have not been evaluated. For the time being, clinicians should seriously consider biopsy in patients with non-alcoholic fatty liver disease. This is especially true for those with intermediate or contradictory results from non-invasive tests. Furthermore, guidelines recommend liver biopsy to diagnosis non-alcoholic steatohepatitis [3] . Like the authors, we also agree that non-invasive tests to determine the presence of steatohepatitis and fibrosis are advancing.
Third, both groups raise issues regarding test cut-offs. Specifically, they argue that the upper limits of normal AST differ between both laboratories and genders and that APRI's cut-off value could be 1.5. In general, arbitrary cut-offs reduce the clinical and statistical power of laboratory tests. Additionally, we agree that the prevalence of significant liver disease beneath the so-called 'upper limits of normal' (ULN) should not be ignored [4, 5] . APRI is just one helpful piece of information that assists in clinical decision-making.
In principle, one could optimize the characteristics of the APRI test by adjusting its parameters. In response to the specific criticisms, we show below how, the lower the cut-off, the higher the sensitivity and the lower the specificity of APRI (Table 1) . However, there are many powerful tests for the non-invasive prediction of fibrosis [6, 7] . APRI's comparative advantage is its ease of use. The power of APRI could be improved, but at the cost of complexity. One could render it into a continuous variable with a beta coefficient or adjust the precise cut-off to some fraction other than our figure of 1.0, or by using different AST cut-offs. Yet, no matter how far optimized, it is unlikely to compete for accuracy with more sophisticated tests [6] . The virtue of APRI is-and always has been-its simplicity [8] . 
